Challenges in meta-analysis of randomized clinical trials for rare harmful cardiovascular events: The case of rosiglitazone
To access this article, please choose from the options below
PII: S0002-8703(08)00162-2
doi:10.1016/j.ahj.2008.03.002
© 2008 Mosby, Inc. All rights reserved.
